UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038135
Receipt number R000043463
Scientific Title A study to evaluate the effects of test food on autonomic nerve activity: a randomized, double-blind, placebo-controlled, crossover trial
Date of disclosure of the study information 2020/09/30
Last modified on 2020/07/29 12:08:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study to evaluate the effects of test food on autonomic nerve activity: a randomized, double-blind, placebo-controlled, crossover trial

Acronym

A study to evaluate the effects of test food on autonomic nerve activity

Scientific Title

A study to evaluate the effects of test food on autonomic nerve activity: a randomized, double-blind, placebo-controlled, crossover trial

Scientific Title:Acronym

A study to evaluate the effects of test food on autonomic nerve activity

Region

Japan


Condition

Condition

Healthy Japanese subjects

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify the effects of test food on autonomic nerve activity in healthy subjects.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Heart rate variability

Key secondary outcomes

Neuropsychological tests for cognitive functions
Visual Analogue Scale (VAS) of fatigue


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Period I. the test food
Period II. control food

* The intervention sequence is Period I to II.
* Washout period is for approximately 1 week.

Interventions/Control_2

Period I. control food
Period II. the test food

* The intervention sequence is Period I to II.
* Washout period is for approximately 1 week.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

1.Subjects who use Japanese as his/her primary language
2.Subjects who are judged as healthy by the physician from screening (scr) test

Key exclusion criteria

Subjects who
1. cannot identify color
2. have difficulty taking cognitive function tests because of weak sight or hearing
3. have 26 scores or less of MMSE
4. have a symptom, have been diagnosed, have a history, and/or have a daily medication for the following items: amblyopia, blindness, deafness, anacusis, cerebral nervous disease, cardiac disorder, depressive symptoms, depression, menopausal syndrome, sleep-related diseases, cardiac arrhythmia, and/or serious disease
5. are receiving hormonal therapy, or treatment related to cognitive function
6. have a pacemaker
7. sometimes have irregular lifestyles during study
8. have the following situation more than once a week: [taking drugs, or health foods that influence cognitive function, autonomic nerve activity, or improving sleep], or [taking foods resembling test food or energy drink]
9. having a habit of drinking beverages relating test foods more than once a month, regardless of amount, or cannot abstain from drinking the beverages between 1 week before scr test and the end of the test period
10. regularly drink alcohol beyond proper quantity
11. are smokers, or started smoking cessation within the last 12 months before scr
12. have experienced cognitive function tests within the last 12 months before scr
13. have donated whole blood or got a blood transfusion within the last 3 months before scr
14. have been enrolled in other clinical trials within the last 1 month before scr, or planning to participate during the test period
15. have a risk of allergies to the test food
16. are pregnant or lactation
17. are judged inappropriate as subjects from answers to lifestyle questionnaires
18. are not successfully taken his/her data of autonomic nerve activity at scr
19. or whose family who living together work at a company developing and manufacturing functional foods
20. plan to do the following during the test period: go abroad, donate blood, pregnant or lactation
21. are judged as unsuitable by doctor

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Kazuo
Middle name
Last name YAMAMOTO

Organization

ORTHOMEDICO Inc.

Division name

CEO

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.

TEL

03-3818-0610

Email

kazu@orthomedico.jp


Public contact

Name of contact person

1st name Naoko
Middle name
Last name SUZUKI

Organization

ORTHOMEDICO Inc.

Division name

R&D Department

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.

TEL

03-3818-0610

Homepage URL


Email

nao@orthomedico.jp


Sponsor or person

Institute

ORTHOMEDICO Inc.

Institute

Department

Personal name



Funding Source

Organization

Kirin Holdings Company, Limited

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Medical Corporation Seishinkai, Takara Clinic

Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethical committee of the Takara Clinic, Medical Corporation Seishinkai

Address

9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan.

Tel

03-5793-3623

Email

info@takara-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)


Other administrative information

Date of disclosure of the study information

2020 Year 09 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

34

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 09 Month 09 Day

Date of IRB

2019 Year 09 Month 09 Day

Anticipated trial start date

2019 Year 10 Month 01 Day

Last follow-up date

2019 Year 12 Month 21 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 09 Month 27 Day

Last modified on

2020 Year 07 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043463


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name